Varex Imaging Corporation (VREX) Q4 2025 Earnings Call Transcript

Varex reported a strong FY25 finish with Q4 revenue of $229m (+11% y/y) at the high end of guidance—Medical $152m (+5%) and a record Industrial quarter $77m (+25%)—driving FY revenue of $845m (+4%); non‑GAAP gross margin expanded to 34% in Q4 (35% for the year, +230bps), non‑GAAP EPS was $0.37 in Q4 and $0.90 for the year, adjusted EBITDA was $122m, cash was $155m after using ~$75m to retire convertible debt, and net leverage fell to ~1.8x TTM EBITDA. Momentum was led by security screening and cargo systems (>$55m in orders and 15+ systems shipped), a ramp of radiographic detector production from a new India facility, and continued progress on photon‑counting CT with OEM partners and a Technical University of Munich demonstrator; China anti‑dumping probes have been paused indefinitely. For Q1 management guides $200–215m revenue and $0.05–0.25 non‑GAAP EPS with expected gross margin 32–34%; they flag a 100–150bps tariff drag but are mitigating via price increases, tariff pass‑through and supply‑chain regionalization, while key catalysts (India tube factory ~12–15 months away, additional photon‑counting design‑ins and lumpy cargo system shipments) will determine margin and growth trajectory amid concentrated customer exposure (top 10 = 52% of sales).

Analysis

Varex delivered a stronger-than-expected finish to FY25 with Q4 revenue of $229 million, up 11% year-over-year and at the high end of guidance; Medical contributed $152 million (+5%) while Industrial posted a record $77 million (+25%). Non-GAAP gross margin expanded to 34% in Q4 (35% for the year, +230 bps year-over-year), non-GAAP EPS was $0.37 in Q4 and $0.90 for the year, trailing‑12‑month adjusted EBITDA was $122 million, cash ended at $155 million after a ~$75 million convertible debt retirement, and net debt was roughly $215 million implying ~1.8x leverage.

Industrial strength was driven by security screening and cargo systems (>$55 million booked and 15+ systems shipped), while Medical showed CT tube strength and continued R&D investments — notably photon‑counting progress with OEM partners and a Technical University of Munich demonstrator. Management has begun ramping radiographic detector production in India, with a tubes factory ~12–15 months from shipments, and China anti‑dumping probes are paused indefinitely.

Management guides Q1 revenue $200–215 million and non‑GAAP EPS $0.05–0.25 with gross margin 32–34%, but flags a 100–150 bps tariff drag, high customer concentration (top 10 = 52% of sales) and lumpy system shipments as key near‑term volatility risks; primary catalysts to monitor are cargo backlog conversion, India ramp cadence and photon‑counting design‑ins.

Key Decisions for Investors

• Consider accumulating VREX on pullbacks to capture Industrial momentum and margin expansion, but size positions conservatively given 52% top‑10 customer concentration and tariff uncertainty
• Monitor Q1 results versus guidance and track cargo‑system shipment cadence, India detector ramp and photon‑counting OEM design‑ins as the primary catalysts that should materially change the mid‑term thesis
• Implement downside protection or position limits (options or smaller exposure) until tariff outcomes and China supply‑chain visibility improve because tariffs are a 100–150 bps gross‑margin headwind
• Use net leverage and cash trends as a risk filter: if net debt/adjusted EBITDA remains around or below ~1.8x and cash stabilizes, consider incremental exposure; if leverage reverses, reduce exposure